## Pathophysiology of Chronic Kidney Disease Stage 3 Moderate (N18.3)Chronic Kidney Disease (CKD) Stage 3, also known as moderate CKD, is characterized by a persistent decrease in the glomerular filtration rate (GFR) to a range of 30-59 mL/min/1.73 m² for three months or more, irrespective of the underlying cause. This stage signifies a significant reduction in kidney function, where the kidneys are no longer able to efficiently filter waste products, maintain fluid and electrolyte balance, regulate blood pressure, produce erythropoietin, or activate vitamin D. The progressive loss of nephron mass leads to compensatory hyperfiltration and hypertrophy in the remaining nephrons, which, over time, contributes to further injury and fibrosis. Key pathophysiological mechanisms include intraglomerular hypertension, activation of the renin-angiotensin-aldosterone system (RAAS), oxidative stress, inflammation, and fibrosis. These processes lead to a vicious cycle of kidney damage, exacerbating the decline in GFR. At this stage, various metabolic abnormalities begin to manifest due to the accumulation of uremic toxins. These include imbalances in calcium and phosphate metabolism, leading to secondary hyperparathyroidism and renal osteodystrophy. Anemia, primarily due to decreased erythropoietin production by the kidneys, also becomes more common. Furthermore, the impaired excretion of potassium and acid can lead to hyperkalemia and metabolic acidosis, respectively. The systemic inflammation and endothelial dysfunction associated with CKD contribute significantly to the increased risk of cardiovascular disease, which is the leading cause of morbidity and mortality in CKD patients. ### Clinical Presentation Patients with CKD Stage 3 often present with subtle or non-specific symptoms, making early diagnosis challenging. Many individuals may remain asymptomatic, especially in the early phase of Stage 3 (GFR 45-59 mL/min/1.73 m²). However, as kidney function further declines (GFR 30-44 mL/min/1.73 m²), symptoms tend to become more noticeable. Common clinical manifestations include fatigue and weakness, resulting from anemia or accumulation of uremic toxins. Peripheral edema, particularly in the lower extremities, may develop due to fluid retention and impaired sodium excretion. Changes in urination patterns, such as nocturia (frequent nighttime urination) or polyuria, can occur as the kidneys lose their concentrating ability. Gastrointestinal symptoms like anorexia, nausea, and a metallic taste in the mouth are also possible. Musculoskeletal complaints, including bone pain, joint pain, and muscle cramps, may arise from mineral and bone disorders. Neurological symptoms such as difficulty concentrating, memory impairment, and restless legs syndrome can also be present. Hypertension is common and often difficult to control, contributing to further kidney damage and increasing cardiovascular risk. Skin changes, such as pruritus (itching) and pallor, are also observed in some patients. ### Diagnostic Criteria The diagnosis of CKD Stage 3 is primarily based on persistent evidence of decreased kidney function. The key diagnostic criteria are: 1. **Estimated Glomerular Filtration Rate (eGFR)**: An eGFR between 30 and 59 mL/min/1.73 m² sustained for at least three months. This is calculated using serum creatinine, age, sex, and race (though race-based equations are being re-evaluated). 2. **Markers of Kidney Damage (if eGFR is ≥60 mL/min/1.73 m² but evidence of damage exists)**: While not the primary criterion for Stage 3, kidney damage (e.g., albuminuria, hematuria, pathological abnormalities on biopsy, structural abnormalities on imaging) must be present to diagnose CKD at any stage if the eGFR is above 60. For Stage 3, the GFR criteria alone define the stage. **Diagnostic Investigations**: * **Blood tests**: Serum creatinine (to calculate eGFR), blood urea nitrogen (BUN), electrolytes (sodium, potassium, bicarbonate), calcium, phosphorus, parathyroid hormone (PTH), complete blood count (CBC) to check for anemia, and hemoglobin A1c for diabetic patients. * **Urine tests**: Urinalysis to check for proteinuria, hematuria, and casts. Urine albumin-to-creatinine ratio (UACR) to quantify albuminuria, which is a critical marker for kidney damage and risk stratification. * **Imaging studies**: Renal ultrasound is often performed to assess kidney size, look for hydronephrosis, cysts, stones, or other structural abnormalities, and differentiate between acute and chronic kidney injury. * **Kidney biopsy**: May be considered in specific cases to determine the underlying cause of kidney disease, especially when the etiology is unclear or rapidly progressive, or when there are signs of systemic disease. ### Standard of Care The management of CKD Stage 3 focuses on slowing the progression of kidney disease, managing complications, and reducing the risk of cardiovascular events. **1. Blood Pressure Control**: Aggressive blood pressure management is crucial. The target blood pressure is typically <130/80 mmHg, although individualized targets may be considered. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are first-line agents, especially in patients with albuminuria, as they reduce proteinuria and slow CKD progression. **2. Glycemic Control**: For patients with diabetes, strict glycemic control (HbA1c target usually <7%) is vital. Newer agents like SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated renoprotective and cardioprotective benefits in CKD with or without diabetes. **3. Dietary Modifications**: * **Sodium Restriction**: Limiting sodium intake to <2 grams/day helps control blood pressure and fluid retention. * **Protein Restriction**: A low-to-normal protein diet (0.8 g/kg/day) may help reduce uremic load and slow progression. * **Potassium and Phosphorus Management**: Dietary restriction may be necessary if hyperkalemia or hyperphosphatemia develops. Phosphate binders may be prescribed. **4. Anemia Management**: Anemia should be investigated and treated. Iron supplementation is often the first step. Erythropoiesis-stimulating agents (ESAs) may be used if iron stores are adequate and hemoglobin levels remain low. **5. Mineral and Bone Disorder Management**: Regular monitoring of calcium, phosphorus, and PTH. Vitamin D supplementation (native or active forms) and phosphate binders may be required to manage secondary hyperparathyroidism and renal osteodystrophy. **6. Lifestyle Modifications**: Encouraging smoking cessation, regular physical activity, and maintaining a healthy weight. **7. Regular Monitoring**: Patients with CKD Stage 3 require regular monitoring of eGFR, UACR, blood pressure, electrolytes, and other relevant labs to track disease progression and manage complications. Referral to a nephrologist is often recommended, especially for patients with a rapid decline in GFR, significant albuminuria, resistant hypertension, or complex complications.